Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety and efficacy of fluzoparib combined with
abiraterone in neoadjuvant treatment of patients with high-risk localized prostate cancer.